BIRMINGHAM, Ala., May 1, 2024 /PRNewswire/ -- On May 1, Encompass Health opened its call for research grant applications due Sept. 30 at 5 p.m. CST. The grants, totaling up to $50,000, will be awarded for the investigation of the impact or effectiveness of therapies in the inpatient rehabilitation facility post-acute care setting, knowledge translation or implementation science. Grant recipients do not have to be affiliated with Encompass Health and research does not have to be conducted in an Encompass Health inpatient rehabilitation hospital.
High priority topics include:
Applications will be evaluated based on scientific merit, experience of principal investigator(s), relevance to the grant program objectives, expected outcomes, and study feasibility. The research should be completed no more than 12 months after receiving the grant and must be conducted in the United States or Puerto Rico. Final selection of recipients and programs will be made by Oct. 30.
A copy of the application and the full details may be found at encompasshealth.com/therapy-grants.
About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of rehabilitation hospitals in the United States. With a national footprint that includes 160 hospitals in 37 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's World's Most Admired Companies and Modern Healthcare's Best Places to Work in Healthcare. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.
MEDIA CONTACT:
Polly Manuel | 205-970-5912
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$113.85 |
| Daily Change: | -2.96 -2.53 |
| Daily Volume: | 2,048,053 |
| Market Cap: | US$11.470B |
October 29, 2025 August 07, 2025 August 04, 2025 June 18, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
